Okay. We'll kick this off. Good morning, and welcome to the Jefferies Global Healthcare Conference in London. My name is Mike Sarcone, and I'm an analyst on the U.S. Medical Supplies and Devices team here, and this is a session with Henry Schein. From the company, we have Fred Lowery, CEO, Emmanuel Caprais, CFO, and Graham Stanley, who heads IR. Gentlemen, thank you very much for joining us today.
Good morning.
Yeah, thanks for having us.
Awesome. I guess just to kick it off, Fred, we can start with you. You've been in the seat about nine months now. I guess, maybe give us an update on how your experience has been in the first nine months, and any surprises you've experienced to the upside or downside versus your expectations coming in.
Yeah, thanks for having us today. Excited to be here, and I would tell you, coming into the role, I was very excited to join Henry Schein, an iconic brand in the space, and really the leader in this space. I was excited about the opportunity, but I will tell you, eight months into the role, I am even more excited than I was coming in the door, and it is because of a few things. One, I have obviously learned a lot more about the business and about the industry, but I see even more opportunity, and it starts for us with our technology business. I mean, we have a great presence there. We are seeing very good growth.
What is really exciting is that the capabilities that we are adding to the platform, to our PMS platform, are really being accepted by customers, and I think that bodes well for continued growth in that space. Ultimately, it becomes the centerpiece of the platform that we are building to support our customers, and so that we are more than just a supplier, but more of a partner in helping them improve their practices. It starts with our technology business, but it continues through our service business, through our specialty products business, and of course, through our distribution business. So, I am even more bullish eight months into the role, and we are making good progress. We are taking market share in dental, and we are committed to deliver on our value creation actions that are helping us expand our operating income.
I feel like we are in a great spot, and the future is bright.
All right, great. Good to hear. Maybe, on the high-level strategy question, wanted to touch on Schein's BOLD+1 strategy. A big piece of this, though not the only piece, is shifting the mix toward higher growth, higher margin businesses. I guess, can you give us an update on where Schein stands in that journey today, and what are the competitive advantages that support that shift?
Yeah, so our stated goal was that we would get to over 50% of our income coming from high-growth and high-margin products by 2027, and we are on track to do that. We will exit this year at that rate. I would also say it is not done. That mix shift that we are seeing to our high-growth, high-margin businesses will continue.
I just spoke about our technology business, our PMS platform, where we are seeing good growth, both from a share of wallet standpoint and from new placements of our cloud-based platform, both the Dentrix Ascend and Dentally platforms. So, that will continue, and we will see good growth in our specialty products, which is another portion of our high-growth, high-margin business, where we are seeing good growth in our implant business in Europe. We are seeing good growth in our value implant business in the U.S.
We are very excited about the S.I.N. 360 business, and we are seeing new products being launched into that business. We feel good about us continuing to see that mix shift into high-growth, high-margin as a part of our operating income.
All right, great. Maybe we can loop in Emmanuel. You are a few weeks into the role. I guess first, can you talk about what attracted you to Schein, and then second, can you talk about how your background and experience make you well-positioned to execute on key priorities at Schein?
Yeah, thank you, Mike. I think what attracted me was to join a market-leading healthcare platform. We have a very capillary distribution network. Henry Schein has a lot of competitive advantages, and so being able to contribute to that was really attracting to me. So, driving growth, driving profitable growth, driving cash generation are going to be my focus in supporting Fred to implement his mission and his vision. I think in terms of my industrial background, I come from a place where we drive profitable growth. We are very focused on cash, and so that is what I intend to implement and to help drive at Henry Schein. I think this is a company that has a lot of really strong positions and very passionate people.
I think that when you have a lot of competence to work with, you can direct and guide people in a more effective way and make up a little bit for that maybe developing market knowledge, the situation that I'm in. I think that great base to work with, looking forward to add and drive profitable growth as well as cash generation.
All right, thank you for that. I guess just to squeeze one in, we saw an update yesterday from Schein about taking out the remeasurement gains and rebasing some of the P&L. I guess, can you speak to the timing around that and what you hope to accomplish?
Yeah. I think, I realize that the remeasurement gains are providing difficult readability of legibility of the numbers. It's very lumpy, so it didn't really belong to operational performance, so that's why we decided to exclude them for our results. We think it's going to provide a more direct read on how the company is performing. For us, that was the first step, small first step to show the operational improvement in the operational discipline that we want to instill in the business. Yeah, I think, I wouldn't say it's a major change.
It's just providing better visibility to our operational performance, then I think that this is what we intend to do. We intend to drive really good results and then be able to simply explain how we're doing that.
Makes a lot of sense. Then, with that new rebased guidance, right, and again, you got this question multiple times on the 3Q call, the commitment to double-digit-
Yeah
EPS growth. When we think about the base for 2026, I think you still have the $0.19 tariff benefit in there. Do we think about double-digit off of that base with or without the tariff benefit in there?
Let me start by saying that we will not be providing 2027 guidance. I think it's way too early for that. And the team, most importantly, the teams are still working on our 2027 budget. For sure, we confirm the commitment to grow double digits in 2027 and beyond, compared to 2026. Obviously, when we made that commitment, we didn't have the tariff refund, so that applies to the base without the tariff refund. As far as 2027 actual guidance, we're still working on it, and so I think it's too early for me to comment, what will be the growth out of the reported number at the end of the year.
Understood, but really appreciate the color there. Then, maybe shifting to pricing. On the pricing dynamics, we've seen ongoing consolidation among dental customers via DSOs, and we've also seen increasing competition from online distributors. I guess, Fred, can you provide us an update on what you're seeing in terms of pricing dynamics? Has anything changed? In 3Q, you called out healthy U.S. dental merchandise growth primarily from volume, and that's some share gains. So I guess, any update ultimately on how you're thinking about pricing and Schein's power in the market?
Yeah, thanks for the question. One of the components of our value creation is around improving our ability to drive price. We have added capabilities in this area, both with people, tools, and systems. We are improving our insight, and it has given us the ability to make better decisions to be able to both drive price up where we have opportunities and doing that responsibly and from a value standpoint, but also to be able to lower price in areas where it makes sense for us to lower price to be more competitive and take share. That is the major shift for us, is that we have got better capabilities to be able to do that and provide better insight to our teams in that regard.
From a market standpoint, no, there is no real change in the pricing dynamic of when our suppliers raise prices, when there is inflation, we are able to pass on that price appropriately. In cases where our customers are looking for a better value or a lower price option, we have those options in our portfolio, which oftentimes are our own brands or our private label products. We are able to use those levers to both manage inflation, the inflationary environment. Also, just when I think about the DSOs model, and you mentioned the consolidation of DSOs, we are very heavily weighted in DSOs, and that is a great part of our business. It helps us grow faster. In particular, the emerging DSOs where you have practices that are in a 20+ , 20- 80 range. Those practices are growing much faster.
From our perspective, while there may be some pricing or negotiating power that DSOs have, we actually have a lower cost to serve with DSOs because we do not have a sales rep going to every one of the offices that is a member of a DSO. Frankly, a lot of the DSOs do not want us to have sales reps going there because they have a formulary, and they are helping to encourage and drive the formulary in their practices. Our lower cost to serve really puts us in good footing. Because of the DSOs' ability to manage their business, they are oftentimes very interested in buying more of our own brands, and that also plays to our advantage. The consolidation and the growth of DSOs is actually quite positive for us. We are not just seeing growth in DSOs.
As I mentioned in our call, if I look sequentially from Q1 to Q2 and from Q2 to 3Q, we saw really good growth, growing growth in private practices. I think that bodes well toward our growth strategy also.
You and I discussed this in a previous conversation, but I think worth highlighting. Can you talk about this improved pricing capability? Does that span across all different channels and customer types, from private practices to emerging DSOs and much larger DSOs?
Yeah. I think there are opportunities to drive the appropriate price across multiple segments of the market. I mean, clearly there are competitive dynamics in any account, and we understand that and take that into account. Having better price discipline and price visibility allows us to be more competitive where we need to be, but also drive the appropriate price where we have the opportunity and where the value is there.
Okay. Very helpful. I guess, did want to touch on macro. For dental, the macro environment has been a concern for a while. You said it's mostly stable, called out some pressure on discretionary procedure spend, though you don't have big exposure there. I guess, can you talk to us about what you're seeing on the macro front? Any changes, either improvements or worsening that you can speak of?
Yeah. No, I mean, we just spoke about this a few weeks ago. No major changes from our perspective. We still see pretty steady market conditions, and the market is stable. For our business, when you think about patient traffic, we think it is tied more toward employment rates because if patients are employed, they have insurance, then patient traffic seems to be pretty steady. That's kind of more of an indication versus consumer sentiment, which sort of impacts the more discretionary portions of the market, where we're not as heavily weighted from our portfolio standpoint. So we think the market is steady. Then the other part of it is that we're participating in the faster-growing parts of the market, both from a DSO perspective, emerging DSO perspective, but also the technology business. It's a much faster part of the market from our perspective.
Yeah. I do want to get into the technology business, but I did want to touch on capital equipment demand first. Maybe you can give us an update there as well on what you are seeing in the different parts of the capital equipment market.
Yeah. From an equipment standpoint, when I look at the order book for Q4, we are seeing sequential growth and year-over-year growth. We expect to see growth in equipment in Q4. Just remember, 2/3 of our equipment business is more traditional equipment, and 1/3 is kind of more digital equipment. I would say that on the traditional equipment side, we are seeing growth. On the digital equipment side, we are seeing volume growth, but not overall revenue growth. That is primarily because of the trend of seeing lower price entrants in portions of that market. But the volume growth on digital is actually very good for us because it says that customers are actually doing more in their practices likely, and we are seeing that benefit from a merchandise standpoint.
When you do see that digital equipment adoption, does it typically follow that you will see a lift in merchandise sales after that?
Yeah, I think in general you see a lift in merchandise sales just because the productivity goes up. Yeah.
Gotcha. On technology, that has been a nice source of growth for the company. I guess, what do you view as a sustainable growth rate in that business, and what are the major drivers of growth for you as you look forward?
Yeah, we are excited about the technology business. Our PMS, our cloud-based PMS platform, Dentrix Ascend and Dentally, are seeing good growth in two ways. One, as we launch new capabilities, we are seeing adoption of those capabilities, and customers are moving from their current package to a higher package, which implies a more expensive package, in order to get those new capabilities because they are seeing value from those. So that is the share of wallet piece of growth that we are seeing from that business. But within also, we are seeing the conversion from on-prem to cloud-based, and our cloud-based products are growing. We are adding around 200 new installations per month, which is quite fast growth, and we are excited about that growth. The overall business is growing in the 8% range now, as it has been this year.
We think it can grow 8%-12%, so we think there is real upside in this technology business. It is a great indication of how technology is changing dentistry. The exciting part is that we are not only creating new capabilities leveraging AI, but we are also implementing AI capabilities that others are creating because people want to be on our cloud-based platform, and it continues to make it easier for our customers to do business. So that is the exciting part, that we are helping to drive productivity in the practices.
All right. You mentioned 8%-12%. Is there anything specific in the near term that drives that acceleration from 8%, where you are kind of right now, or that is just
No, I think it is the thing that I just described. It is the new placements and share of wallet gains and continuing to add new capabilities that encourage customers to be excited to implement the new system.
Okay. I did want to ask, you mentioned value creation initiatives. You have got the strategic partnership with KKR. I guess, can you elaborate on some of the key components there and how you are thinking about the operating income targets and milestones we should be looking out for?
Yeah, from a value creation standpoint, we are on track to deliver a $125 million run rate of impact relative to the 2025 base by the end of this year, end of 2026, and $200 million impact, get to that run rate at some point in 2028. There is really a few components of it. It is starting on the improvement in our gross margin, and I have already mentioned earlier our pricing capabilities that we have added. I think it is a really important point to note is, while we have committed to these numbers, it is not a one-and-done kind of thing. We add new capabilities, we will continue to see the benefit from having better capabilities around pricing over time.
The other area is to accelerate the growth of our own brands, and we are seeing that today through different tactics that we are using and adding focus there, and we are seeing our own brands grow almost twice as fast as our third-party brands. So that is exciting. On the cost side, we have created a centralized indirect sourcing team to focus on leveraging our scale of our purchases, and that is going well.
We have announced that we are outsourcing some of our back office functions, starting with some areas of finance and customer service, and that really just started in 3Q. Of course, there is some overlapping costs as you bring on new people that we are seeing, so we expect to see more savings from that in 2027 versus in 2026. But we are in process there in execution mode, and over time, we will add other functions to that.
We expect that to continue driving benefit in 2027.
If I can add on the pricing, I think we are really in the early phase of the pricing, even though we are generating benefits. We have made some progress to structure that action. There is still a lot of benefits that are to come. Really, the focus is really to make sure that we capture the value that we deliver. Customer do recognize that value for sure, and we need to make sure that it flows through the P&L as well.
Got it. That makes sense. I guess, is there any way to quantify, you have a target of hitting a run rate of $125 million of operating income by year end, maybe how much you have achieved year to date through the 3Q? Any way to quantify that?
We have not quantified that, and I think the reason is because we do not want for the value creation to be seen as accessory or incremental to what we are doing. It is part of what we are doing. It is very much a productivity program. It is embedded in the way we do things, and it is also expected to generate recurring benefits. We are not going to quantify, and I think the best proof of that it is working is the fact that we are creating value, we are delivering double-digit EPS growth. It has been the third quarter in a row, year-over-year, and we intend to continue to do that, as I said, in 2027.
Got it. Fred, you mentioned some of your targeted limited investments have been bearing fruit, particularly on the U.S. merchandise side. You are going to make some incremental investments in 4Q. I guess, can you elaborate on the types of investments you are making and how long that may take to bear fruit? In the broader context, can you talk about the decision framework you use to balance that investment spend versus the double-digit EPS growth target?
Yeah, we are certainly committed to double-digit EPS growth, and we see these investments as being an enabler toward continuing to be able to do that. The fact that we are taking share in the dental business, it really started with some of the investments that we made and the promotions that we did back in Q2 of 2025. We learned a lot from that, and in particular, we learned how to encourage what I would call episodic customers who maybe were shopping their business around, to become active customers. What we are using the promotions and the investments in Q4 to do is to really engage our customers more closely. What we found is, as we get closer with our customers, they tend to continue to buy from us, and so we are excited to be able to do that.
I would say, I would just characterize the investments as limited and very targeted, and as we see benefit, we can push a little harder in areas that maybe where we are not seeing benefit, we can redeploy that others. We expect to see the upside in 2027, just like from the investments we made in Q2, we started to see that benefit later in the year and into this year. So, we are excited about continuing to engage customers and continue to take share in dental.
All right, great. We have about a minute left, so maybe we can just close it out on any updates on, or just give us kind of how you think about capital deployment priorities in the near to midterm.
Yeah, and thanks. I did not know you would ask me. Yeah, thanks for the time today. We are excited about driving more value for our shareholders. From a capital deployment standpoint, as we have looked at how we can do that this year, we have tended to be a little more aggressive from a share repurchase standpoint. However, I will tell you, I think M&A is still a part of, especially bolt-on M&A, is still an opportunity for this business. We will keep our eyes open and we will be a little more disciplined probably than prior management on what we might acquire, but it will be focused on helping us continue to build out this platform that enables our customers to run their businesses better.
Those are the type of opportunities we would be looking for, and those things would obviously be focused on driving more organic growth and driving great returns to our shareholders.
Yeah. I think that what is the key tenet of the capital deployment is incremental cash generation. I think that as we drive this business to generate more cash, we will not have to necessarily make arduous choices between the different aspects of the capital deployment, and we will be able to do everything that Fred said, and in addition to this, reduce debt.
Okay, great. Well, that is all the time we have, so thank you very much, Fred, Emmanuel, and Graham, and for the audience, thank you for your time.
Thank you.
Thank you.